CoImmune Announces Collaboration with Top U.S. Cancer Center to Accelerate Development of CAR-CIK Therapies to Treat Solid Tumors

DURHAM, N.C., Oct. 18 (Korea Bizwire) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced a license and collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the adaptation of CoImmune’s proprietary allogeneic CAR-CIK technology platform to treat solid tumors. Under the terms [...]

Chimeric Antigen Receptor (CAR)-modified Cytokine Induced Killer Cell (CAR-CIK) Technology Featured at ASH

DURHAM, N.C., Dec. 16 (Korea Bizwire) — CoImmune, Inc. today announced that its CAR-CIK technology was featured at the annual American Society of Hematology (ASH) meeting with an interim update on the phase 1/2 dose escalation clinical trial in B-cell acute lymphoblastic leukemia (B-ALL). The trial is being conducted at Ospedale San Gerardo, Monza, Italy [...]